Application
SR 49059 has been used to study the V1AR (vasopressin type 1A receptor) signaling mediated β adrenergic receptor responsiveness and its contribution to the development of heart failure.
SR 49059 may be used in Arginine Vasopressin (AVP) V1a-receptor-mediated cell signaling studies.
Biochem/physiol Actions
SR 49059 is a potent and selective Arginine Vasopressin (AVP) V1a-receptor antagonist. AVP is a hormone that plays an important part in circulatory and water homoeostasis and is important in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF). There are three AVP receptor subtypes V1a, V1b, and V2. All belong to the large rhodopsin-like G-protein-coupled receptor family. V(1a) antagonists improve water balance and cardiac hypertrophy in CHF and might be beneficial for the treatment of water retention and cardiac remodeling in CHF. SR 49059 has also shown initial positive results in the treatment of Raynaud′s disease, dysmenorrhoea, and tocolysis.
Features and Benefits
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
5, 25 mg in glass bottle
This product has met the following criteria to qualify for the following awards: